<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01498055</url>
  </required_header>
  <id_info>
    <org_study_id>GLiang</org_study_id>
    <nct_id>NCT01498055</nct_id>
  </id_info>
  <brief_title>Autologous CIK Cells Infusion for the Treatment of Lung Cancer: a Randomized Controlled Study</brief_title>
  <acronym>CIK</acronym>
  <official_title>A Randomized Controlled Trail on the Efficacy and Safety of Autologous Cytokine-induced Killer (CIK) Cells Infusion Treatment in Advanced Primary Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the efficacy and safety of autologous CIK cells infusion for the treatment of lung
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized controlled trail on the efficacy and safety of autologous cytokine-induced
      killer (CIK) cells infusion treatment in advanced primary lung cancer
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rates (DCR)</measure>
    <time_frame>From 12-2011 to 12-2013</time_frame>
    <description>Lung lesions of disease control rates DCR (CR + PR + SD), according to solid tumor response evaluation standard (response evaluation criteria in solid tumors, RECIST) standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Disease progression-free surial (Progression-Free Srvival, PFS) with observations</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CIK therapy group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The one-time folic acid sodium anticoagulation vacuum picks bag, through the venous blood
      sampling 60 ml. When blood alcohol on parts of the need blood disinfects processing. After
      the department shows will seal in a sterile bag, 16-21 degrees Celsius save, and transported
      to a cell biological treatment as soon as possible a follow-up operation center GMP
      laboratory.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary lung cancer diagnosis (including small cell lung cancer, lung adenocarcinoma, lung
        squamous cell carcinoma and large cell carcinoma) patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18~70 year old, KPS score &gt;50 points, estimate survival &gt; 3 months;

          -  Primary lung cancer patients after chemotherapy or radiation therapy;

          -  Primary lung cancer patients after targeted therapy;

          -  Primary lung cancer patients with lung function can not accept operation or unwilling
             to operation;

          -  Primary lung cancer recurrence or surgery can't complete resection;

          -  Primary lung cancer patients after intervention therapy(I125 implanted, freezing, rf,
             etc.);

          -  No serious mental illness and no serious heart, liver, kidney diseases, unincorporated
             other potentially lethal diseases;

          -  Patients Voluntary attempt, and informed consent.

        Exclusion Criteria:

          -  History of cardiovascular disease: congestive heart failure &gt; New York heart
             association (NYHA) level II, unstable angina patients (resting when the angina
             symptoms) or new happen angina pectoris (recent 3 months) or recent 6 months of
             myocardial infarction;

          -  Cachexia; or other deadly diseases;

          -  Liver function laboratory ALT, AST more than normal limits on 2.0 times ; Or kidney
             TBIL, BUN more than normal limits on 1.0 times , or Cr more than normal upper limit;

          -  Active infection;

          -  Pregnant or lactating women

          -  At present Is receiving other cancer treatment (such as chemotherapy, radiation
             therapy, chemotherapy, immunosuppressants and thrombosis, targeted agents);

          -  Now or recently will join another experimental clinical study ;

          -  Other situations that the researchers considered unsuitable for this study (such as
             mental illness, drug abuse, HIV infections, etc.), or influence on the results of
             clinical trials for analysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiangdong Zhou</last_name>
    <role>Study Chair</role>
    <affiliation>Southwest Hospital Third Military University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liang Gong</name>
      <address>
        <city>Chong Qing</city>
        <state>Chong Qing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Gong</last_name>
      <phone>13983965893</phone>
      <email>gonglw1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Liang Gong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2011</study_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Gong Liang</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>CIK cells</keyword>
  <keyword>therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

